No Data
The Zacks Analyst Blog Highlights Roche, Poseida Therapeutics, Merck, AstraZeneca and Novartis
Top Stock Reports for Chevron, AstraZeneca & Arista Networks
Trump 'sells off' European pharmaceutical stocks, can only rely on 'Americanization' to stop the decline?
The growth prescription for European pharmaceutical companies: shifting towards the usa.
Astrazeneca (AZN.US) Class 1 new drug approved for clinical trials in China for the first time, aiming to develop treatment for heart failure.
Astrazeneca (AZN.US) has received an implied license for clinical trials of its Class 1 new drug AZD5462 in china, which is intended for the treatment of heart failure.
Express News | The latest study in The Lancet: a historic breakthrough in the treatment of asthma and COPD.
AstraZeneca Partner's Orpathys Secures Renewal on China's Drug Reimbursement List